PHARMACOLOGICAL EVALUATION OF MARKETED POLYHERBAL FORMULATION
Introduction: - Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder that may affect many tissues and organs â€“ skin, blood vessels, heart, lungs and muscles. But principally attacks the joints, producing a non-supportive proliferative sinusitis that often progresses to destruction of the articular cartilage and ankylosis of the joints. Rhumapar tablet is a marketed polyherbal formulation believed to have the potential for providing relief to rheumatoid arthritis (RA) patients.
Objective: - Investigations have been carried out using rats as experimental models, to assess the anti inflammatory and anti arthritic potential of Rhumapar tablet. In-vitro anti-oxidant study has been carried out using different in-vitro models.
Result:- The results obtained demonstrate that Rhumapar tablet can significantly and dose-dependently inhibit carrageenan-induced rat paw oedema (the inhibition at 3 hour was greater than at 1 hour after induction of oedema).Tablet can also significantly inhibit granuloma formation in cotton pellet induced granuloma model. It also showed significant anti-arthritic activity in Freund's complete adjuvant (FCA) induced arthritis. The responses were statistically significant when they were compared with the control.
Conclusion: - It has been indicated that formulation possesses anti- inflammatory and anti-arthritic activities that are probably mediated through inhibition of prostanoid synthesis and free radical scavenging effect.
Keywords: Rhumapar tablet, Rheumatoid arthritis, Anti-inflammatory activity, Anti-arthritic activity, Anti-oxidant activity.
Borris P. J. Ethno pharmacol. 1996; 51:29.
Achike FI, Kwan CY. Nitric oxide, human diseases and the herbal products that affect the nitric oxide signalling pathway. Clin Exp Pharmacol Physiol 2003; 30: 605-15.
Aruoma OI. Use of DNA damage as a measure of pro-oxidant actions of antioxidant food additives and nutrient components.1993: 315â€“327.
Barbier A, Novarro JC, Brelliere RR. Biochemical and clinical changes in rats with the developing arthritis. 1984; 15:103-105.
Chattopadhyay P, Besra SE, Gomes A. Life Sciences 2004; 74:1839-1849.
Chaudhari SC, Chaudhari SR, Chavan MJ. Asian Pacific Journal of Trophical Biomedicine. 2012:S181-S186.
Feldman DL, Mogelesky TC, Sharif R, Sawyerw JM. The in vitro and ex vivo antioxidant properties and hypolipidemic activity of CGP 2881.1999; 144: 343â€“355.
Ilavarasan R, Mallika M. Afr. J. Trad. Cam. 2005; 2: 70 â€“ 85.
Krane SM, Conca W, Stephenson MI, Amento EP, Goldring. Annals of the New York Academy of Sciences. 1990; 580: 340â€“354.
Kumar RS, Sivakumar T, Sunderam RS, Gupta M, Mazumdar UK. Brazilian Journal of Medical and Biological Research.2005; 38:1015-1024.
Mondal SK, Muzumder UK. Indian J Experimental Biology. 2006; 44: 39-44.
Oyaizu M. Jpn. J. Nutr. 1986; 31: 307-315.
Patwardhan B, Gautam M. Drug Discov Today.2005; 7: 495â€“502.
Prakash BN, Pandikumar P, Ignacimuthu S. J Ethno pharmaco. 2009; 125: 356-360.
Rajlakshmi D, Banerjee SK. Journal of Pharmacy and Pharmacology. 2003; 55:1681-1686.
Shinde UA, Phadke AS, Nair AM, Mungantiwar AA, Dikshit VJ, Saraf MN. J. Ethano Pharmaco. 1999; 65:21-27.
Singh S, Majumdar DK, Rehan HMS. J. Ethno Pharmaco. 1998; 54: 19-26.
Speroni E, Cervellati R, Innocenti G, Costa S, Guerra MC, Govoni, P. J. Ethano pharmacol. 2005; 98:117-125.
Sreejayan, Rao MN. Journal of Pharmacy and Pharmacology.1997; 49: 105-107.
Thangam C, Dhananjayan R. Indian J. Pharmacol. 2003; 35: 388-391.
Yen.V. J. Agri. Food Chem. 1997; 45:30-34.
Yin W, Wang TS, Yin FZ, Cai BC. J Ethno pharmacol. 2003; 88:205-214.
Khandelwal K.R. Practical Pharmacognosy techniques and experiments. 6th ed. Nirali Prakashan, Nasik, 1999: 23-28.
Kokate, C.K. Experimental Pharmacognosy 1st ed. Nirali Prakashan, New Dehli, 1985:24-32.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.